RxDoctor Payments Data

Amanda Smallmon, APRN

Psychiatric/Mental Health · Piggott, ARNPI 1447481072

Payments from drug & device makers

$1,772in general payments, 2019–2025

Across 63 payments — averaging $28.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$786
  • AbbVie$485
  • Supernus Pharmaceuticals, Inc.$220
  • Axsome Therapeutics, Inc.$98
  • Otsuka America Pharmaceutical, Inc.$67
  • Takeda Pharmaceuticals U.S.A., Inc.$46
  • plus $70 from 4 others

What the payments were for

  • Travel & lodging$1006%
  • Food & beverage$1,67294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,772 in reported general payments places this provider in the 65th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$29,051
Medicare patients
28
Services billed
424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl85$152,064
AuvelityDextromethorphan Hbr/Bupropion39$45,997
RexultiBrexpiprazole13$19,296
JardianceEmpagliflozin12$7,291
LinzessLinaclotide12$6,629
JanuviaSitagliptin Phosphate11$6,438
Varenicline Tartrate14$2,876
Vilazodone Hcl29$2,701
Aripiprazole80$1,945
Fluvoxamine Maleate37$1,512
Albuterol Sulfate HfaAlbuterol Sulfate29$1,366
Duloxetine Hcl99$1,268
Lurasidone Hcl37$1,093
Doxepin Hcl54$883
Quetiapine Fumarate55$860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$786$152,06485 claims
Axsome Therapeutics, Inc.Auvelity$98$45,99739 claims
Otsuka America Pharmaceutical, Inc.Rexulti$67$19,29613 claims
AbbVieLinzess$485$6,62912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Piggott

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →